EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments

Yen-Shou Kuo, Ming-Yi Zheng, Yi-Shing Shieh, Tsai-Wang Huang, Yu-Ting Chou iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yen-Shou Kuo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Carcinoembryonic Antigen, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tri-Service General Hospital, National Science and Technology Council, Taiwan, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Serum carcinoembryonic antigen (CEA) has potential prognostic and monitoring significance in lung adenocarcinoma (LUAD) patients undergoing different treatments, such as epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) and chemotherapy. The changes in CEA expression during relapses, influenced by resistance mechanisms involving cytokines and epigenetic factors, may impact its utility in disease prognosis, monitoring, and management.

Methods

This retrospective study analyzed advanced LUAD patients treated between 2011 and 2018, including 182 patients receiving EGFR‐TKIs and 102 undergoing chemotherapies. Serum CEA levels were measured at baseline and relapse. Associations between CEA levels, treatment modalities, and survival outcomes were assessed using Cox regression and Kaplan–Meier analyses. Gene expression profiling and in vitro experiments explored the regulation of CEACAM5 expression by cytokines and epigenetic mechanisms in EGFR‐TKI‐resistant cells.

Results

Elevated baseline CEA (≥ 5 ng/mL) was associated with significantly worse overall survival (OS) in patients treated with EGFR‐TKIs but showed no prognostic value in chemotherapy‐treated patients. During the relapse, EGFR‐TKI–treated patients were more likely to exhibit a transition to CEA‐negative status (< 5 ng/mL) compared to those receiving chemotherapy. Mechanistic studies revealed that EGFR‐TKI‐resistant cells displayed reduced CEACAM5 expression and increased epithelial‐to‐mesenchymal transition (EMT) markers, driven by cytokine signaling and epigenetic modifications.

Conclusions

Serum CEA is a stronger prognostic biomarker for LUAD patients treated with EGFR‐TKIs while offering consistent monitoring capabilities in chemotherapy‐treated patients. These findings highlight the differential clinical value of serum CEA in guiding therapeutic strategies and monitoring disease progression across treatment modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungCarcinoembryonic AntigenLung NeoplasmsProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleErbB ReceptorsRetrospective StudiesMiddle AgedPrognosisAgedDrug Resistance, NeoplasmBiomarkers, TumorGPI-Linked ProteinsAdult

Stichwörter der Autor:innen

biomarkercarcinoembryonic antigen (CEA)chemotherapyepidermal growth factor receptor (EGFR)epithelial‐to‐mesenchymal transition (EMT)lung adenocarcinoma (LUAD)tyrosine kinase inhibitor (TKI)

Substanzen

Carcinoembryonic AntigenErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanBiomarkers, TumorCEACAM5 protein, humanGPI-Linked Proteins

Autor:innen und Institutionen

  • Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
  • Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.
  • Department of Dentistry, Tri-Service General Hospital, Taipei, Taiwan.
  • National Defense Medical University, Taipei, Taiwan.

ORCID-Profile: Yu-Ting Chou

Förderung

  • Tri-Service General Hospital
  • National Science and Technology Council, Taiwan
  • National Science and Technology Council

Zitieren

APA

Kuo, Y. S., Zheng, M. Y., Shieh, Y. S., Huang, T. W., & Chou, Y. T. (2025). Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments. Cancer Medicine. https://doi.org/10.1002/cam4.71170

Vancouver

Kuo YS, Zheng MY, Shieh YS, Huang TW, Chou YT. Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments. Cancer Medicine. 2025. doi:10.1002/cam4.71170

BibTeX
@article{Kuo2025,
  author = {Kuo, Yen-Shou and Zheng, Ming-Yi and Shieh, Yi-Shing and Huang, Tsai-Wang and Chou, Yu-Ting},
  title = {Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71170}
}
Kostenlos starten →